Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ostrolux
- Development stage
- Unknown
- Lead developer
- 3V Medical Research Group
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Ostrolux is a topical analgesic cream developed by 3V Medical Research Group for the management of pain associated with osteoarthritis, radiation dermatitis, and other chronic pain conditions. Its active ingredient, 3VM1000, is a patent-protected formulation consisting of a suspension of copper compounds in a dilute copper solution. The drug's mechanism of action involves binding to opioid receptors at the site of application to provide a local analgesic effect. The formulation utilizes Versabase, a widely used cream base, to facilitate transdermal absorption of the active copper compounds. It is currently being evaluated in Phase 1/2 clinical studies, with an Investigational New Drug (IND) status.
- Brand names
- Ostrolux
Beyond the preview
Go deeper on Ostrolux.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ostrolux.